What is Encellin?
Founded in 2015, Encellin is at the forefront of regenerative materials science. The company specializes in cell transplant therapy, utilizing a unique soft cell encapsulation device that functions as a protective, semi-permeable pouch. This technology allows transplanted cells to survive within the host body while acting as smart molecular factories that release therapeutic agents on demand. By addressing the fundamental challenges of cell viability and immune rejection, Encellin is positioning itself as a leader in the treatment of chronic diseases that require precise, long-term therapeutic delivery. Its market position is defined by its ability to bridge the gap between laboratory-scale cell therapy and scalable, clinical-grade medical devices.
How much funding has Encellin raised?
Encellin has raised a total of $15.8M across 2 funding rounds:
Angel/Seed
$5.9M
Other Financing Round
$9.9M
Angel/Seed (2021): $5.9M with participation from Y Combinator, Khosla Ventures, SV Latam Capital, and Sandhill Angels
Other Financing Round (2023): $9.9M led by Y Combinator and Khosla Ventures
Key Investors in Encellin
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
Khosla Ventures
A prominent venture capital firm focused on early-stage and growth-stage investments in technology, healthcare, and sustainability sectors.
SV Latam Capital
SV LATAM Capital is the first early-stage VC firm born in Silicon Valley with a distinct focus on investing in Latin American entrepreneurs and science-based startups.
What's next for Encellin?
With the recent infusion of capital, Encellin is poised to advance its clinical trials and refine its manufacturing processes for the CED platform. The strategic focus will likely shift toward regulatory milestones and expanding the therapeutic applications of its encapsulation technology beyond current targets. As the company matures, it will need to demonstrate the long-term efficacy and safety of its devices in human subjects to secure further institutional support. The ongoing partnership with established venture firms suggests a robust roadmap for commercialization, with a clear emphasis on solving complex healthcare problems through innovative, science-driven solutions that promise to transform patient outcomes in the regenerative medicine sector.
See full Encellin company page
